Genesis MedTech Acquires JC Medical, a Structural Heart Company

February 4, 2022—Genesis MedTech Group, based in Singapore, announced it has completed the acquisition of JC Medical (JCM).

JCM, which is based in China with offices in Burlingame, California, is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. With the acquisition, Genesis adds JCM’s J-Valve to its product portfolio. Zhang Ji, the Founder and President of JCM, will continue as President of JCM and will serve as CTO for Genesis’ Structural Heart Franchise.

According to Genesis, J-Valve is a transcatheter aortic valve replacement (TAVR) device for both aortic regurgitation and stenosis patients.

The device is designed to minimize stent migration for improved safety and clinical efficacy. Its design allows for treatment of patients with low coronary ostium height and small sinuses, as well as those requiring aortic and mitral valve-in-valve procedures.

J-Valve consists of both transapical (J-Valve TA) and transfemoral (J-Valve TF) TAVR devices.

The J-Valve TA has been available to treat regurgitation and stenosis patients in China since 2017.

In the United States and Canada, J-Valve TF is limited to compassionate use only. Clinical trials will support FDA premarket approval for full availability in the United States. Also, JCM has been planning to bring J-Valve TF to the Chinese market.

Warren Wang, Chairman and CEO of Genesis MedTech Group commented in the company’s press release, “The acquisition of JCM and J-Valve exemplifies the type of innovations we envisage as part of a growing Genesis portfolio. We are incredibly pleased to start a new structural heart franchise, spearheaded by the best-in-class TAVR solution, J-Valve. By doing this we hope to better support cardiac surgeons and cardiologists in their fight against structural heart diseases.”